Patents Examined by Mindy G Brown
-
Patent number: 10738284Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.Type: GrantFiled: June 4, 2018Date of Patent: August 11, 2020Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, BaltimoreInventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
-
Patent number: 10732171Abstract: Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.Type: GrantFiled: December 20, 2012Date of Patent: August 4, 2020Assignee: The Procter & Gamble CompanyInventors: Deborah Ruth Finlay, Tomohiro Hakozaki, Charles Carson Bascom, Heather Eileen Matheny
-
Patent number: 10711275Abstract: Disclosed are methods and compositions for inhibiting DNA synthesis in a cell using RNA. Inhibition of DNA synthesis by RNA can be used, for example, in analytical methods, as a research tool to affect cells under study, to synchronize cell cycle in a cell culture, and to inhibit cell growth. For example, inhibition of DNA synthesis in cancer cells can be used to inhibit cancer cells and treat cancer. The RNA can be any RNA, such as whole cell RNA, whole cell mRNA, whole cell ribosomal RNA, whole cell transfer RNA, synthetic RNA, recombinant RNA, modified RNA, or a combination. The composition can comprise RNA and a pharmaceutically acceptable carrier or RNA, a targeting molecule, and a pharmaceutically acceptable carrier. The targeting molecule can be a tumor-targeting peptide.Type: GrantFiled: July 11, 2014Date of Patent: July 14, 2020Inventor: Zhen Huang
-
Patent number: 10711281Abstract: The present invention relates to adeno-associated viral vector useful for transducing adipose tissue. The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vector. The invention also relates to gene therapy methods useful for the treatment of a disease that requires the regulation of the expression levels of a gene.Type: GrantFiled: August 2, 2013Date of Patent: July 14, 2020Assignee: Universitat Autónoma de BarcelonaInventors: Verónica Jiménez Cenzano, Fátima Bosch Tubert
-
Patent number: 10711267Abstract: This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes as well as plasmids, retroviruses and bacteriophage comprising the same.Type: GrantFiled: September 25, 2019Date of Patent: July 14, 2020Assignee: NORTH CAROLINA STATE UNIVERSITYInventors: Rodolphe Barrangou, Claudio Hidalgo-Cantabrana
-
Patent number: 10689640Abstract: The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous recombinant protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous recombinant protein of interest in a periplasm compartment or may secrete the heterologous recombinant protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.Type: GrantFiled: December 19, 2016Date of Patent: June 23, 2020Assignee: Pfenex Inc.Inventors: Diane M. Retallack, Charles H. Squires, Thomas M. Ramseier, Russell J. Coleman, Jane C. Schneider, Charles D. Hershberger
-
Patent number: 10682378Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.Type: GrantFiled: December 4, 2017Date of Patent: June 16, 2020Assignee: THE TRUSTEES OF DARTMOUTH COLLEGEInventors: Tong Zhang, Charles L. Sentman
-
Patent number: 10676721Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.Type: GrantFiled: September 2, 2011Date of Patent: June 9, 2020Assignees: Trustees of Boston University, Massachusetts Institute of TechnologyInventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
-
Patent number: 10669541Abstract: Methods for generating mammalian cells characterized by an increased concentration of at least one of miR-15, miR-16, and miR-34 for producing proteins at an industrial scale are provided. Methods for using the mammalian cells, in particular for the production of proteins of interest, are also provided.Type: GrantFiled: July 30, 2014Date of Patent: June 2, 2020Assignee: LONZA BIOLOGICS PLC.Inventors: Marc Feary, James Rance, Robert Young, Elizabeth C. Sayer, Christopher M. Smales
-
Patent number: 10669550Abstract: The invention discloses a promoter which can be induced to express in acidic conditions, and relates to the field of bioengineering technology. The promoters of the invention are separated from A. niger and can actuate and/or regulate the expression of the effectively connected nucleic acids in A. niger. In the invention the expression of the promoters is studied in A. niger, and it is indicated that some promoters show weak expression, and some show strong activity. The invention provides an effective method and new thought for organic acids production by fungi or other products produced by fermentation under acidic conditions.Type: GrantFiled: January 28, 2019Date of Patent: June 2, 2020Assignee: JIANGNAN UNIVERSITYInventors: Long Liu, Jian Chen, Guocheng Du, Xian Yin, Jianghua Li
-
Patent number: 10669585Abstract: Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes.Type: GrantFiled: June 28, 2016Date of Patent: June 2, 2020Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Hei-Mun Christina Fan, Stephen R. Quake
-
Patent number: 10662424Abstract: Provided herein is a method for fabricating transformable or transfectable molecules that includes an assembly reaction containing a variety of pre-made cassettes possessing ends that hybridize to one another, transforming or transfecting said molecules into a desired host cell and then selecting a transformed/transfected host cell containing plasmid molecules composed of said the cassettes. A kit for performing the method is also provided.Type: GrantFiled: October 2, 2013Date of Patent: May 26, 2020Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Jeffrey Carl Braman, Peter James Sheffield, Gavin Fischer
-
Patent number: 10662418Abstract: Provided herein are recombinant microorganisms having two or more copies of a nucleic acid sequence encoding xylose isomerase, wherein the nucleic acid encoding the xylose isomerase is an exogenous nucleic acid. Optionally, the recombinant microorganisms include at least one nucleic acid sequence encoding a xylulose kinase and/or at least one nucleic acid sequence encoding a xylose transporter. The provided recombinant microorganisms are capable of growing on xylose as a carbon source.Type: GrantFiled: March 12, 2018Date of Patent: May 26, 2020Assignee: Mara Renewables CorporationInventors: Alexandra Merkx-Jacques, David Woodhall, Mark Scaife, Roberto E. Armenta, Denise Muise, Holly Rasmussen, Jeremy Benjamin
-
Patent number: 10648012Abstract: Methods and systems for identifying inhibitors of Equilibrative Nucleoside Transporters are provided. Methods and systems for identifying inhibitors of Concentrative Nucleoside Transporters are also provided.Type: GrantFiled: January 8, 2014Date of Patent: May 12, 2020Assignee: Albert Einstein College of MedicineInventors: Myles Akabas, Ithiel James Frame, Roman Deniskin
-
Patent number: 10647984Abstract: The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.Type: GrantFiled: January 3, 2017Date of Patent: May 12, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLEInventors: Nicolas Pottier, Bernard Mari, Brice Marcet, Pascal Barbry
-
Patent number: 10633665Abstract: The present disclosure generally relates to novel polynucleotide molecules for use in regulating gene expression in recombinant cells, such as labyrinthulomycetes cells. The disclosure further relates to nucleic acid constructs, such as vectors and expression cassettes, containing a regulatory element operably linked to a heterologous nucleotide sequence. The disclosure further relates to methods for stably transforming a host cell, such as a labyrinthulomycetes cell with transgenes. Stably transformed recombinant cells, progeny, biomaterials derived therefrom, and methods for preparing and using the same are also provided.Type: GrantFiled: March 8, 2018Date of Patent: April 28, 2020Assignee: Conagen Inc.Inventors: Nicky C. Caiazza, Maung Nyan Win, Jun Urano
-
Patent number: 10619144Abstract: The present invention relates to a recombinant fungal host cell comprising at least one first polynucleotide encoding a polypeptide of interest; and one or more second polynucleotide encoding a fungal PepC protease, wherein the one or more second polynucleotide is operably linked to a regulated heterologous promoter, as well as a method for producing a polypeptide of interest, comprising cultivating said fungal host cell.Type: GrantFiled: August 22, 2014Date of Patent: April 14, 2020Assignee: Novozymes A/SInventors: Hiroshi Teramoto, Hiroaki Udagawa, Jan Lehmbeck, Michael Lynge Nielsen
-
Patent number: 10597650Abstract: Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.Type: GrantFiled: March 14, 2013Date of Patent: March 24, 2020Assignee: New England Biolabs, Inc.Inventors: Gregory Lohman, Thomas C. Evans, Larry A. McReynolds
-
Patent number: 10597710Abstract: Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.Type: GrantFiled: August 28, 2015Date of Patent: March 24, 2020Assignee: New England Biolabs, Inc.Inventors: Gregory Lohman, Thomas C. Evans, Jr., Larry A. McReynolds
-
Patent number: 10584347Abstract: The present invention provides recombinant host cells that produce proteins or therapeutic proteins, and nucleic acid constructs for producing the cells. The cells have nucleic acid constructs that encode a heterologous protein, for example an antibody. The nucleic acid constructs also can have a functional signal sequence that directs the secretion of the protein from the cell. The signal sequence can be any functional signal sequence, and various signal sequences are disclosed herein. The invention also provides methods of producing the proteins.Type: GrantFiled: March 15, 2017Date of Patent: March 10, 2020Assignee: Conagen Inc.Inventors: Nicky C. Caiazza, Jun Urano, Maung N. Win, Kent S. Boles